Impact of Gonadotrophin Releasing Hormone Analogues on Oocyte and Embryo Quality
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The first In-Vitro Fertilization cycles were performed in natural unstimulated cycles. Today
gonadotrophins are administered to induce multiple follicular development and controlled
ovarian hyperstimulation. During ovarian stimulation gonadotrophin-releasing hormone
analogues are co-administered in order to prevent premature luteinizing hormone surges.
Premature luteinizing hormone surges are observed in about 20% of stimulated cycles without
using gonadotrophin-releasing hormone analogues .
Avoiding the adverse effects of elevated luteinizing hormone levels, first
gonadotrophin-releasing hormone agonist analogues were used to supplement the gonadotrophin
stimulation. The continuous administration of gonadotrophin-releasing hormone agonists causes
gonadotrophin suppression through down-regulation and desensitization of the
gonadotrophin-releasing hormone receptors in the pituitary gland after an initial short
period of gonadotrophin hypersecretion .
Gonadotrophin-releasing hormone antagonists (cetrorelix and ganirelix) cause immediate and
rapid gonadotrophin suppression by competitive antagonism of the gonadotrophin-releasing
hormone receptor in the pituitary without an initial period of gonadotrophin hypersecretion.
Several advantageous effects of cetrorelix were established , and these effects seemed to be
independent from the type of antagonist used for luteinizing hormone-suppression.The quality
of oocytes and developing preembryos is one of the most relevant factors determining the
success of an In-Vitro Fertilization treatment. As ovarian stimulation protocol is one of the
eligible factors during an In-Vitro Fertilization treatment, its embryo quality influencing
effects are necessary to know.